Vivo Capital

Chentai New Materials integrates the R&D, design, manufacturing, and sales of high-performance composite ceramics. It Specializes in the innovation and creation of medical high-performance ceramic products.

Abeona Therapeutics is a clinical-stage biopharmaceutical company focused on developing and delivering gene therapy-based treatments for severe and life-threatening rare genetic diseases. Its pipeline includes therapies for Sanfilippo syndrome types A and B, epidermolysis bullosa, Batten disease, cystic fibrosis, and genetic eye disorders.

Ronovo Surgical is an emerging medtech company dedicated to advancing minimally invasive surgery (MIS) through innovative robotic technology. The company has developed a soft tissue surgery robot platform that utilizes next-generation robotics and advanced digital solutions to enhance surgical precision and efficiency. By focusing on various surgical specialties, Ronovo aims to optimize patient outcomes and improve health economics, particularly within the Chinese medical industry. Their efforts are designed to transform surgical care by delivering more effective and less invasive surgical options.

Ossium Health, Inc. is a biotechnology company that specializes in developing and manufacturing advanced cell therapy products aimed at treating blood cancers, improving organ transplantation, and repairing tissue damage caused by radiation exposure. Established in 2016 and based in San Francisco, the company has created a range of therapies, including HPC, Marrow, which consists of human leukocyte antigen (HLA)-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients. Additionally, Ossium offers Chimera, designed to enhance organ transplantation, and Chymalis, which utilizes mesenchymal stem cells from bone marrow to facilitate the healing of damaged bone and muscle tissue. The company also supplies bone marrow cells for research in oncology, immunology, and related fields, focusing on improving health and longevity through innovative bioengineering techniques.

Ronovo Surgical is an emerging medtech company dedicated to advancing minimally invasive surgery (MIS) through innovative robotic technology. The company has developed a soft tissue surgery robot platform that utilizes next-generation robotics and advanced digital solutions to enhance surgical precision and efficiency. By focusing on various surgical specialties, Ronovo aims to optimize patient outcomes and improve health economics, particularly within the Chinese medical industry. Their efforts are designed to transform surgical care by delivering more effective and less invasive surgical options.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.

Founded in 2009, Neocis specializes in robotic guidance systems for dental implant procedures. Its flagship product, Yomi, is a precision instrument that assists surgeons in placing dental implants using advanced robotics and planning software.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.

Tebra is a company that provides a medical technology platform and related services to independent healthcare practices and medical billing organizations. The platform includes patient acquisition, care management through a certified electronic health record system, patient engagement, and billing management, helping providers streamline operations, improve patient care, and strengthen financial performance. By delivering digital tools and support designed to unify disparate practice processes, Tebra aims to be the backbone that enables independent practices to thrive in a changing healthcare landscape.

Cerebral Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Aurora, Colorado, focused on developing innovative drug-device combination therapies for neurologic diseases, particularly refractory epilepsy. The company employs a unique implanted, refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose of valproic acid, an anti-epileptic drug formulated as CT-010. By utilizing reformulated off-patent drugs delivered directly to the brain's ventricles, Cerebral Therapeutics aims to bypass the blood-brain barrier, thereby enhancing treatment outcomes for patients suffering from chronic neurological conditions. Established in 2010, the company is committed to improving the quality of life for those with uncontrolled neurological disorders.

Scientech Medical engages in the research, development, and manufacturing of interventional medical devices.

Ocelot Bio is a biopharmaceutical company focused on developing therapies for severe liver disease, researching medicines to treat hepatorenal syndrome and advancing a therapeutic peptide that targets portal hypertension–related complications in end-stage liver disease to improve outcomes for patients with advanced liver disease.

Histowiz is a biotechnology company established in 2012, specializing in histology services for cancer researchers. It processes, embeds, cuts, stains, and digitizes mouse tissue specimens, offering automated pathology solutions to academia and pharmaceutical clients.

Inbrace is a medical device company focused on revolutionizing orthodontic treatment with its innovative device that aligns teeth discreetly behind the teeth. This system utilizes patented self-guiding technology to apply continuous forces, allowing for gentle teeth correction while minimizing discomfort and reducing the frequency of dental visits compared to traditional methods. Inbrace aims to enhance patient confidence and satisfaction by addressing common concerns associated with orthodontic treatment. The company incorporates digital treatment planning, computer modeling, and direct digital manufacturing to provide a scalable, personalized solution that meets the diverse needs of orthodontic patients. With its FDA registration, Inbrace is positioned to disrupt the orthodontics market and drive practice growth for dental clinicians.

Scientia Vascular is a medical device company that develops, manufactures, and markets endovascular devices for neuro, peripheral, and coronary vascular access. It offers optimized devices and therapies for interventional procedures and has developed the PLATO micro-catheter for treatment of hemorrhagic and ischemic strokes. The company applies micromachining and microfabrication to create a pipeline of vascular access products and therapeutic devices that enable high-precision performance near the site of therapy. Headquartered in Salt Lake City, Utah, Scientia Vascular aims to support complex, minimally invasive procedures and improve patient outcomes with devices designed for enhanced control and precision at the treatment site.

Ronovo Surgical is an emerging medtech company dedicated to advancing minimally invasive surgery (MIS) through innovative robotic technology. The company has developed a soft tissue surgery robot platform that utilizes next-generation robotics and advanced digital solutions to enhance surgical precision and efficiency. By focusing on various surgical specialties, Ronovo aims to optimize patient outcomes and improve health economics, particularly within the Chinese medical industry. Their efforts are designed to transform surgical care by delivering more effective and less invasive surgical options.

Ossium Health, Inc. is a biotechnology company that specializes in developing and manufacturing advanced cell therapy products aimed at treating blood cancers, improving organ transplantation, and repairing tissue damage caused by radiation exposure. Established in 2016 and based in San Francisco, the company has created a range of therapies, including HPC, Marrow, which consists of human leukocyte antigen (HLA)-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients. Additionally, Ossium offers Chimera, designed to enhance organ transplantation, and Chymalis, which utilizes mesenchymal stem cells from bone marrow to facilitate the healing of damaged bone and muscle tissue. The company also supplies bone marrow cells for research in oncology, immunology, and related fields, focusing on improving health and longevity through innovative bioengineering techniques.

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that incorporates a proprietary dry-powder formulation of dihydroergotamine mesylate. Designed for self-administration, STS101 utilizes a pre-filled, single-use nasal delivery device, enhancing patient convenience and accessibility. The product is currently undergoing Phase III clinical trials, marking a significant step in its development. Founded in 2016, Satsuma is headquartered in South San Francisco, California.

dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

Elevation Oncology develops precision medicines for genomically defined cancers. Its lead candidate, seribantumab, inhibits tumor growth driven by NRG1 fusions, currently in Phase 2 trials.

Founded in 2009, Neocis specializes in robotic guidance systems for dental implant procedures. Its flagship product, Yomi, is a precision instrument that assists surgeons in placing dental implants using advanced robotics and planning software.

PatientPop, Inc. is a practice growth platform that aids medical providers in enhancing their operations and patient engagement. Founded in 2014 and based in Santa Monica, California, the company offers a comprehensive suite of services designed to streamline the patient journey. These services include website development, search engine optimization, online scheduling, appointment reminders, reputation management, and integration with electronic medical records. PatientPop's platform focuses on attracting new patients, managing online reputation, and automating front-office tasks, thereby allowing healthcare providers to concentrate on delivering quality patient care. By automating and improving key touchpoints in the patient experience, PatientPop empowers medical practices to thrive in the digital age.

Preventice Solutions, Inc., established in 2007, specializes in healthcare technology solutions. The company offers a range of services, sensors, and software to remotely monitor and manage patient health data, primarily focusing on cardiac care. Key products include the PatientCare Portal, a self-managed cloud platform for real-time patient data management; BodyGuardian Heart, a pocket-sized wearable monitor for enhanced patient mobility and compliance; and BodyGuardian Verité, a dual-modality remote cardiac sensor for physicians. Preventice Solutions operates from Eagan, Minnesota, with additional offices in Fargo, North Dakota, San Francisco, California, and Houston, Texas.

Remegen is a Chinese biopharmaceutical company focused on developing novel biologics, primarily monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), to address unmet medical needs in life-threatening conditions. Headquartered in Yantai with labs/offices in Beijing and California, Remegen's portfolio includes Telitacicept for systemic lupus erythematosus and Disitamab Vedotin for various cancers.

ALX Oncology is a clinical-stage immuno-oncology company based in Burlingame, California, established in 2015. The company specializes in developing innovative therapies aimed at treating various forms of cancer, with a particular focus on its lead product candidate, ALX148. This therapeutic agent is designed to block the CD47 protein, which cancer cells exploit to evade the immune system. ALX148 is currently being investigated for its efficacy in treating myelodysplastic syndromes, acute myeloid leukemia, and several solid tumor types, including head and neck squamous cell carcinoma and certain gastric cancers. The company leverages advanced protein engineering technologies to enhance the affinity of its CD47 blockers, aiming to minimize hematologic toxicities often associated with existing treatments. ALX Oncology's commitment to improving cancer therapies is rooted in pioneering research conducted by its founders at Stanford University.

Aligos Therapeutics is a biopharmaceutical company dedicated to developing innovative therapeutics targeting viral infections and liver diseases. Founded in 2018, the company focuses on chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH), leveraging its expertise in liver disease drug development.

Cerebral Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Aurora, Colorado, focused on developing innovative drug-device combination therapies for neurologic diseases, particularly refractory epilepsy. The company employs a unique implanted, refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose of valproic acid, an anti-epileptic drug formulated as CT-010. By utilizing reformulated off-patent drugs delivered directly to the brain's ventricles, Cerebral Therapeutics aims to bypass the blood-brain barrier, thereby enhancing treatment outcomes for patients suffering from chronic neurological conditions. Established in 2010, the company is committed to improving the quality of life for those with uncontrolled neurological disorders.

Arcutis Biotherapeutics is a biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. Its lead product, ZORYVE roflumilast cream, has demonstrated symptomatic improvement in plaque psoriasis patients.

dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

Inbrace is a medical device company focused on revolutionizing orthodontic treatment with its innovative device that aligns teeth discreetly behind the teeth. This system utilizes patented self-guiding technology to apply continuous forces, allowing for gentle teeth correction while minimizing discomfort and reducing the frequency of dental visits compared to traditional methods. Inbrace aims to enhance patient confidence and satisfaction by addressing common concerns associated with orthodontic treatment. The company incorporates digital treatment planning, computer modeling, and direct digital manufacturing to provide a scalable, personalized solution that meets the diverse needs of orthodontic patients. With its FDA registration, Inbrace is positioned to disrupt the orthodontics market and drive practice growth for dental clinicians.

Cerebral Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Aurora, Colorado, focused on developing innovative drug-device combination therapies for neurologic diseases, particularly refractory epilepsy. The company employs a unique implanted, refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose of valproic acid, an anti-epileptic drug formulated as CT-010. By utilizing reformulated off-patent drugs delivered directly to the brain's ventricles, Cerebral Therapeutics aims to bypass the blood-brain barrier, thereby enhancing treatment outcomes for patients suffering from chronic neurological conditions. Established in 2010, the company is committed to improving the quality of life for those with uncontrolled neurological disorders.

MacuLogix, Inc. is a company specializing in the diagnosis, monitoring, and treatment of age-related macular degeneration (AMD), a leading cause of blindness. The company develops innovative tools, including the AdaptDx, a fully automated dark adaptometer that allows eye care professionals to assess the dark adaptation process in patients. This technology enables early detection and tracking of AMD, allowing for intervention up to three years before the disease manifests visually. MacuLogix aims to reduce preventable blindness through its screening tools, which are distributed across the United States and internationally, as well as sold online. Founded in 2008 and based in Harrisburg, Pennsylvania, MacuLogix continues to advance its mission to combat vision loss associated with AMD.

AirXpanders, Inc. was a medical device company headquartered in San Jose, California, specializing in the design, manufacture, sale, and distribution of innovative medical devices aimed at improving breast reconstruction outcomes. Founded in 2005, the company developed the AeroForm Tissue Expander System, a needle-free and patient-controlled device specifically designed for use in two-stage breast reconstruction following mastectomy. This system allowed patients to expand tissue in a controlled manner before the insertion of breast implants. Despite its advancements in medical technology, AirXpanders filed for Chapter 7 bankruptcy and ceased operations on September 25, 2019.

Sinovac Biotech Ltd., established in 1999 and headquartered in Beijing, China, is a biopharmaceutical company dedicated to the research, development, manufacture, and commercialization of vaccines against human infectious diseases. Its portfolio includes vaccines for hepatitis A and B, enterovirus 71 (EV71), seasonal influenza, H5N1 and H1N1 pandemic influenza, mumps, and hand, foot, and mouth diseases. Notable products include Healive for hepatitis A, Bilive for combined hepatitis A and B, Anflu for seasonal influenza, Panflu for H5N1 influenza, Panflu.1 for H1N1 influenza, and Inlive for EV71. The company has completed phase III clinical trials for varicella and pneumococcal polysaccharide vaccines and is advancing trials for other vaccines such as Sabin inactivated polio, pneumococcal conjugate, rubella, and quadrivalent influenza. Sinovac collaborates with GlaxoSmithKline Biologicals SA and Tianjin CanSino Biotechnology Inc. for vaccine development. The company primarily sells its vaccines in China and exports to select countries including Mongolia, Nepal, and the Philippines.

Cerebral Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Aurora, Colorado, focused on developing innovative drug-device combination therapies for neurologic diseases, particularly refractory epilepsy. The company employs a unique implanted, refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose of valproic acid, an anti-epileptic drug formulated as CT-010. By utilizing reformulated off-patent drugs delivered directly to the brain's ventricles, Cerebral Therapeutics aims to bypass the blood-brain barrier, thereby enhancing treatment outcomes for patients suffering from chronic neurological conditions. Established in 2010, the company is committed to improving the quality of life for those with uncontrolled neurological disorders.

Aligos Therapeutics is a biopharmaceutical company dedicated to developing innovative therapeutics targeting viral infections and liver diseases. Founded in 2018, the company focuses on chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH), leveraging its expertise in liver disease drug development.

Homology Medicines is a biotechnology company focused on developing genetic therapies for rare diseases. Its proprietary platform uses human hematopoietic stem cell-derived adeno-associated virus vectors to deliver treatments in vivo, targeting various tissues including the liver and central nervous system. The company's lead product candidate, HMI-102, is in clinical trials for treating phenylketonuria.

Angiotech is a Vancouver, British Columbia pharmaceutical company. Its products enhance the performance of medical devices and biomaterials through the use of pharmacotherapeutics. Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury.

Angiotech is a Vancouver, British Columbia pharmaceutical company. Its products enhance the performance of medical devices and biomaterials through the use of pharmacotherapeutics. Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury.

SentreHEART, Inc., located in Redwood City, California, is a privately held medical device company specializing in catheter-based technologies for suturing soft tissues. The company has developed the LARIAT Suture Delivery Device, which allows physicians to remotely deliver a 40mm pre-tied suture loop for effective soft tissue closure through minimally invasive access points as small as 4.3mm. This innovative technology eliminates the need for metal, clips, or fabrics, ensuring a complete and immediate closure without leaving foreign materials in the body. SentreHEART has received regulatory clearance for its device for soft tissue ligation and approximation in the United States, Europe, and Canada, enhancing surgical options and patient safety by reducing the risk of thromboembolism.

AirXpanders, Inc. was a medical device company headquartered in San Jose, California, specializing in the design, manufacture, sale, and distribution of innovative medical devices aimed at improving breast reconstruction outcomes. Founded in 2005, the company developed the AeroForm Tissue Expander System, a needle-free and patient-controlled device specifically designed for use in two-stage breast reconstruction following mastectomy. This system allowed patients to expand tissue in a controlled manner before the insertion of breast implants. Despite its advancements in medical technology, AirXpanders filed for Chapter 7 bankruptcy and ceased operations on September 25, 2019.

TRIA Beauty, Inc. is a developer and marketer of light-based medical devices aimed at the consumer market, specializing in beauty and skincare solutions. Founded in 2003 and headquartered in Dublin, California, the company offers a range of innovative products including a hand-held, cordless diode laser for hair removal, a Skin Perfecting Blue Light device for acne treatment, a Skin Rejuvenating Laser for anti-aging purposes, and an Age-Defying Eye Wrinkle Correcting Laser. These devices utilize advanced light technology, which is preferred by dermatologists for effective skincare treatments, allowing users to achieve professional results at home. TRIA Beauty products are available through its e-commerce platform and various indirect sales channels, including retail outlets, television, and physician offices. The company serves a global market, reaching customers in the United States, Japan, South Korea, Canada, the United Kingdom, Germany, and Spain.

AirXpanders, Inc. was a medical device company headquartered in San Jose, California, specializing in the design, manufacture, sale, and distribution of innovative medical devices aimed at improving breast reconstruction outcomes. Founded in 2005, the company developed the AeroForm Tissue Expander System, a needle-free and patient-controlled device specifically designed for use in two-stage breast reconstruction following mastectomy. This system allowed patients to expand tissue in a controlled manner before the insertion of breast implants. Despite its advancements in medical technology, AirXpanders filed for Chapter 7 bankruptcy and ceased operations on September 25, 2019.

TRIA Beauty, Inc. is a developer and marketer of light-based medical devices aimed at the consumer market, specializing in beauty and skincare solutions. Founded in 2003 and headquartered in Dublin, California, the company offers a range of innovative products including a hand-held, cordless diode laser for hair removal, a Skin Perfecting Blue Light device for acne treatment, a Skin Rejuvenating Laser for anti-aging purposes, and an Age-Defying Eye Wrinkle Correcting Laser. These devices utilize advanced light technology, which is preferred by dermatologists for effective skincare treatments, allowing users to achieve professional results at home. TRIA Beauty products are available through its e-commerce platform and various indirect sales channels, including retail outlets, television, and physician offices. The company serves a global market, reaching customers in the United States, Japan, South Korea, Canada, the United Kingdom, Germany, and Spain.

SentreHEART, Inc., located in Redwood City, California, is a privately held medical device company specializing in catheter-based technologies for suturing soft tissues. The company has developed the LARIAT Suture Delivery Device, which allows physicians to remotely deliver a 40mm pre-tied suture loop for effective soft tissue closure through minimally invasive access points as small as 4.3mm. This innovative technology eliminates the need for metal, clips, or fabrics, ensuring a complete and immediate closure without leaving foreign materials in the body. SentreHEART has received regulatory clearance for its device for soft tissue ligation and approximation in the United States, Europe, and Canada, enhancing surgical options and patient safety by reducing the risk of thromboembolism.

AirXpanders, Inc. was a medical device company headquartered in San Jose, California, specializing in the design, manufacture, sale, and distribution of innovative medical devices aimed at improving breast reconstruction outcomes. Founded in 2005, the company developed the AeroForm Tissue Expander System, a needle-free and patient-controlled device specifically designed for use in two-stage breast reconstruction following mastectomy. This system allowed patients to expand tissue in a controlled manner before the insertion of breast implants. Despite its advancements in medical technology, AirXpanders filed for Chapter 7 bankruptcy and ceased operations on September 25, 2019.

AirXpanders, Inc. was a medical device company headquartered in San Jose, California, specializing in the design, manufacture, sale, and distribution of innovative medical devices aimed at improving breast reconstruction outcomes. Founded in 2005, the company developed the AeroForm Tissue Expander System, a needle-free and patient-controlled device specifically designed for use in two-stage breast reconstruction following mastectomy. This system allowed patients to expand tissue in a controlled manner before the insertion of breast implants. Despite its advancements in medical technology, AirXpanders filed for Chapter 7 bankruptcy and ceased operations on September 25, 2019.

TRIA Beauty, Inc. is a developer and marketer of light-based medical devices aimed at the consumer market, specializing in beauty and skincare solutions. Founded in 2003 and headquartered in Dublin, California, the company offers a range of innovative products including a hand-held, cordless diode laser for hair removal, a Skin Perfecting Blue Light device for acne treatment, a Skin Rejuvenating Laser for anti-aging purposes, and an Age-Defying Eye Wrinkle Correcting Laser. These devices utilize advanced light technology, which is preferred by dermatologists for effective skincare treatments, allowing users to achieve professional results at home. TRIA Beauty products are available through its e-commerce platform and various indirect sales channels, including retail outlets, television, and physician offices. The company serves a global market, reaching customers in the United States, Japan, South Korea, Canada, the United Kingdom, Germany, and Spain.

Vicept Therapeutics, Inc., located in Malvern, Pennsylvania, is a privately held specialty biopharmaceutical company established in August 2009. The company focuses on developing innovative topically applied therapies aimed at treating erythema, or skin redness, associated with rosacea and other dermatological conditions characterized by redness and flushing. In addition to its research and development efforts, Vicept manufactures and distributes dermatological therapeutic products, positioning itself as a key player in addressing the unmet needs of patients with these skin disorders.

Neomend is a biomedical device company focused on developing and commercializing innovative surgical wound healing products. The company's primary technology is Pro/PEG, a bioadhesive polymer hydrogel designed to enhance the healing process. Neomend specializes in a combination wound sealant and adhesion barrier product that can be utilized during minimally invasive and laparoscopic procedures, improving patient outcomes and recovery times. Through its advanced technological solutions, Neomend aims to address critical needs in surgical wound management.

TRIA Beauty, Inc. is a developer and marketer of light-based medical devices aimed at the consumer market, specializing in beauty and skincare solutions. Founded in 2003 and headquartered in Dublin, California, the company offers a range of innovative products including a hand-held, cordless diode laser for hair removal, a Skin Perfecting Blue Light device for acne treatment, a Skin Rejuvenating Laser for anti-aging purposes, and an Age-Defying Eye Wrinkle Correcting Laser. These devices utilize advanced light technology, which is preferred by dermatologists for effective skincare treatments, allowing users to achieve professional results at home. TRIA Beauty products are available through its e-commerce platform and various indirect sales channels, including retail outlets, television, and physician offices. The company serves a global market, reaching customers in the United States, Japan, South Korea, Canada, the United Kingdom, Germany, and Spain.

ViOptix, Inc. is a medical device company that specializes in tissue oximetry technology, which measures local tissue oxygen saturation. Founded in 1999 and headquartered in Fremont, California, ViOptix develops, manufactures, and markets innovative products designed to improve patient outcomes in various medical settings. Its flagship product, the T.Ox Tissue Oximeter, is a lightweight and portable unit that features a color LCD touchscreen and supports multiple fiber optic sensors. Additionally, the company offers T.Ox Remote Monitoring products that enable wireless data transmission to internet-enabled devices, as well as single-use, pre-sterilized sensors for continuous monitoring. The applications of ViOptix's technology span plastic surgery, critical care, and various medical fields, allowing for real-time assessment of tissue viability, wound healing potential, and the detection of vascular diseases. The company, formerly known as Photonify Technologies, Inc., rebranded to ViOptix, Inc. in 2003.